Will the era of domestic biosimilar successes open?
As the first biosimilar, the Sandoz’s ‘Zarxio (generic name: filgrastim)’, has recently acquired sale approvals in the U.S., biosimilars developed by domestic companies have attracted attention of the industry.
As a domestic biosimilar entered the U.S. market, the largest pharmaceutical market, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.